The largest database of trusted experimental protocols

5 protocols using facsfortessa 2

1

Gp120 Stimulation of PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs were stimulated with positive control (S. aureus peptidoglycan) or mock control or with the different gp120 constructs. Cells were washed in PBS containing 2% FBS and 2 mM EDTA, blocked with 10% normal human serum for 15 min at 4°C, and then stained for CD3, CD14, and CD19 (1 μL of each antibody in 100 μL of PBS containing 2% BSA and 2 mM EDTA) for 30 min at 4°C in the dark. Dead cells were excluded using Zombie Aqua Dye (BioLegend). For intracellular staining of IL-10 and TNF- α, Brefeldin A was added 6 hours post-stimulation and cells were cultured overnight. Then, cells were stained for surface markers before being fixed, permeabilized and stained for IL-10 and TNF-α. For intracellular cytokine staining of IL-1, a mix of Brefeldin A, PMA and ionomycin was added 12 hours post-stimulation with gp120 during 4 hours and cells were then fixed and permeabilized for staining. Events were collected on a FACSFortessa II (BD) and analyzed using FlowJo software (Tree Star Inc.).
+ Open protocol
+ Expand
2

Intracellular Staining of Gut and Skin Lymphocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
For intracellular staining, isolated gut and skin lymphocytes were counted for viable cells (1 × 106) and stimulated with PMA (50 ng/mL) and ionomycin (1 μg/mL) for 3 h at 37 °C. Cells were further incubated for 2 h with Golgi stop solution (containing Monesin, final concentration 1 µM), washed with PBS, before surface antigens staining with Thy1.2 (BD, Pharmingen, Clone: 30-H12) and streptavidin conjugated linear markers; NK1.1 (Biolegend, Clone PK136), TCRγδ (BD pharmingen, Clone: GL3), CD11b (BD Pharmingen, Clone: M1/70), CD8α (BD Pharmingen, Clone: 53–6.7), CD19 (ebioscience, Clone: eBio1D3), GR-1 (BD, Clone: RB6-8C5), and Ter119 (BD Pharmingen, Clone: Ter-119) at 4 °C for 15 min. Cells were then incubated with fixation solution (Cytofix, BD) at 4 °C for 50 min, washed twice and stained with intracellular antibodies; RORγt (BD Horizon, Clone: Q31-378), Gata3 (BD Pharmingen, Clone: L50-823), IL-5 (Biolegend, Clone: TRFK5), IL-13 (ebioscience, Clone: eBio13A), IL-17A (Biolegend, Clone: TC11-18H10.1), and IL-22 (Biolegend, Clone: Poly5164) antibodies at 4 °C in the dark for 30 min. Cells were analysed using FACS Canto II or FACS Fortessa II (BD, Biosciences). Cells sorting was performed using FACS Aria III cell sorter (BD, Biosciences). Flow cytometry data were analysed by FlowJo software (version 10.7.1; https://www.flowjo.com/solutions/flowjo).
+ Open protocol
+ Expand
3

THP-1 Monocyte Differentiation and Polarization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Flow cytometry analysis to confirm the differentiation of THP-1 monocytes into Mϕ-like macrophages was performed with anti-CD11b conjugated to allophycocyanin (APC, BioLegend) and anti-CD44 conjugated to phycoerythrin (PE, BD Biosciences) staining. To confirm the polarisation of THP-1 macrophages into M1-like cells, anti-CD38 conjugated to PE-Cy7 (BioLegend) and anti-CD80 conjugated to V450 (BD Biosciences) were used. Cell viability was determined by staining cells with 0.5 μg/ml 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Invitrogen). Acquisition was performed using a BD FACSCanto™ II and a BD FACSFortessa™ II (BD Biosciences) and data were analysed using FlowJo software (BD Biosciences).
+ Open protocol
+ Expand
4

Flow Cytometry Phenotyping of Macrophage Differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Flow cytometry analysis was performed using the following cell surface markers: anti-CD11b conjugated to phycoerythrin (PE, BD Biosciences, clone ICRF44) and anti-CD44 allophycocyanin (APC, BD Biosciences, clone IM7) conjugated to staining to confirm the differentiation of THP-1 Mo into Mϕ. Anti-CD38 conjugated to PE-Cy7 (BioLegend, clone HIT2) and anti-CD80 conjugated to V450 (BD Biosciences, L307.4) to confirm the polarisation into M1-like cells. Anti-CD209 conjugated to BV421 (BD Biosciences, DCN46) to confirm the polarisation into M2-like cells. Cell viability was determined by staining cells with 0.5 μg/ml DAPI (Invitrogen). Acquisition was performed using a BD FACSCanto™ II and a BD FACSFortessa™ II (BD Biosciences) and data were analysed using FlowJo software (BD Biosciences).
+ Open protocol
+ Expand
5

Multiparametric Flow Cytometry of Immune Cell Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies including CD3-FITC (clone OKT3; 1:150, BioLegend, San Diego, CA, USA), CD56 PE/Cy7 (clone NCAM1; 1:50, BioLegend), CD69-PE (clone FN50; 1:60, BD Biosciences, Heidelberg, Germany), CD107a-PE (clone H4A3; 1:25, BD Biosciences) and the corresponding isotype controls were obtained from BioLegend. 7-AAD (BioLegend) staining (1:200) or LIVE/DEAD™ Fixable Violet (1:1000, Thermo Fisher Scientific, Waltham, MA, USA) were used to identify non-viable cells within flow cytometric samples. For flow cytometric assays, 30,000 target cells were incubated in 96-well plates with 65,000 PBMCs, Rituximab at 2.5 µg/mL and various tyrosine kinase inhibitors at the indicated concentrations. After 4 and 24 h, flow cytometric analyses were performed to determine CD107a and CD69 expression, respectively. NK cells were identified as CD56+ CD3+, activated subsets as CD69+. CD107a expression indicated degranulation. Detailed gating strategies are provided in Supplementary Figure S1. All samples were analyzed using the BD FACS Canto II or BD FACS Fortessa II (BD Biosciences, Heidelberg, Germany). Data analysis was performed using FlowJo V10 software (BD Bioscience).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!